| Revenue growth | ₹736cr in Q4 (+22% QoQ); ₹2,542cr for FY26 (-1% YoY). |
|---|---|
| Margins | EBITDA margin normalized at 23% in Q4; guidance to maintain this range. |
| Demand visibility | Positive India demand; recovery in CPVC and caustic soda utilization. |
| Management confidence | Confident in FY27 volume growth of 10-12% post-maintenance. |
Growth
Q4 revenue grew 22% QoQ to ₹736cr; FY26 revenue dropped 1% to ₹2,542cr due to H1 volume de-growth.
Outlook
Targeting 10-12% volume growth in FY27; CPVC/ECH capacity doubling expected by Q2FY27; 90-95% captive chlorine consumption targeted.
Risks
West Asia conflict disrupting supply chains, inflationary raw material costs, and potential monsoon-related demand volatility.
Earnings Call filed with NSE, NSE: EPIGRAL. Summary written with AI assistance from the document.
Epigral Ltd: key numbers
- Share price
- ₹1,036.20
- Market cap
- ₹4,470 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 16.5×Sector 37.2×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 1.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
- Call
- Guides 20% growth
Epigral Capacity Expansion: ₹650 Cr Investment
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
- Value
- ₹650.0 Cr
- Execution
- By H2 FY2028
Epigral Investor Presentation: Key Takeaways
Epigral reported 15% YoY revenue growth and 25% PAT growth for Q1FY27. Strategy focuses on diversifying into high-value derivatives and specialty chemicals with significant capex for Epoxy Resin and Multi-Purpose plants.
- Call
- Guides 70% growth
Epigral Results Update
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
- Value
- ₹600.0 Cr
- Execution
- H2FY28
Epigral Capacity Expansion: ₹600 Cr Investment
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
- Value
- ₹600.0 Cr
- Execution
- By H2 FY2028
Epigral Q1 FY27 Results: Net Profit ₹99.7 Cr, Down 38.0% YoY
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹99.7 Cr · -38.0% YoY